Regional clozapine, ECT and lithium usage inversely associated with excess suicide rates in male adolescents.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 03 2023
14 03 2023
Historique:
received:
31
08
2022
accepted:
20
02
2023
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
Advanced psychiatric treatments remain uncertain in preventing suicide among adolescents. Across the 21 Swedish regions, using nationwide registers between 2016-2020, we found negative correlation between adolescent excess suicide mortality (AESM) and regional frequencies of clozapine, ECT, and lithium (CEL) usage among adolescents (β = -0.613, p = 0.0003, 95% CI: -0.338, -0.889) and males (β = -0.404, p = 0.009, 95% CI: -0.130, -0.678). No correlation was found among females (p = 0.197). Highest CEL usage among male adolescents was seen in regions with lowest quartile (Q1) AESM (W = 74, p = 0.012). Regional CEL treatment frequency in 15-19-year-olds was related to lower AESM in males, reflecting potential treatment efficacy, treatment compliance or better-quality mental health care. Suicide prevention may benefit from early recognition and CEL treatment for severe mental illness in male adolescents. The results indicate association but further research, using independent samples and both prospective and observational methodologies, is needed to confirm causality.
Identifiants
pubmed: 36918566
doi: 10.1038/s41467-023-36973-4
pii: 10.1038/s41467-023-36973-4
pmc: PMC10015020
doi:
Substances chimiques
Clozapine
J60AR2IKIC
Lithium
9FN79X2M3F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1281Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2020 Jan 16;382(3):266-274
pubmed: 31940700
J Am Acad Child Adolesc Psychiatry. 2019 Jan;58(1):25-35
pubmed: 30577936
N Engl J Med. 2020 May 21;382(21):e66
pubmed: 32433855
J Child Adolesc Psychopharmacol. 2020 May;30(4):235-243
pubmed: 32125885
Lancet. 2015 Apr 18;385(9977):1536-44
pubmed: 25579833
Am J Psychiatry. 2021 Jul;178(7):611-624
pubmed: 33596680
Arch Gen Psychiatry. 2003 Jan;60(1):82-91
pubmed: 12511175
Lancet Psychiatry. 2022 Jun;9(6):435-446
pubmed: 35487236
J Child Psychol Psychiatry. 2019 Oct;60(10):1046-1054
pubmed: 31512763
J Child Psychol Psychiatry. 2006 Mar-Apr;47(3-4):372-94
pubmed: 16492264
BMJ. 2013 Jun 27;346:f3646
pubmed: 23814104
Am J Psychiatry. 2006 Nov;163(11):1898-904
pubmed: 17074941
Pediatrics. 2007 Sep;120(3):669-76
pubmed: 17766542
Ophthalmic Physiol Opt. 2014 Sep;34(5):502-8
pubmed: 24697967
Brain Sci. 2020 Aug 26;10(9):
pubmed: 32858969
BMJ. 2019 Feb 6;364:l94
pubmed: 31339847
Cochrane Database Syst Rev. 2021 May 24;5:CD013674
pubmed: 34029378
J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1146-1155
pubmed: 31369795
Epidemiol Psychiatr Sci. 2018 Apr;27(2):186-198
pubmed: 27989254
Mol Psychiatry. 2022 Jan;27(1):606-623
pubmed: 34117365
Front Psychiatry. 2019 May 03;10:294
pubmed: 31130881
Front Psychiatry. 2021 Dec 01;12:731297
pubmed: 34925084
Neuropsychopharmacology. 2022 Mar;47(4):817-823
pubmed: 34561608
Eur J Pediatr. 2022 Feb;181(2):599-607
pubmed: 34476611
Eur Neuropsychopharmacol. 2015 Jun;25(6):857-63
pubmed: 25769917